MARIA ANGELES DE COS

Dr. MARIA ANGELES DE COS

HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA. UNIVERSIDAD DE CANTABRIA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
LCLucía Cañamero
Lucía Cañamero
ABAdalberto Benito
Adalberto Benito
EGElena González-López
Elena González-López
CEClara Escagedo
Clara Escagedo
MRMaría Rodríguez-Vidriales
María Rodríguez-Vidriales
EREMILIO RODRIGO
EMILIO RODRIGO
Measuring the non-pathogenic Torque Teno Virus (TTV) load allows assessing the net immunosuppressive state after kidney transplantation (KTx). Currently, it is not known how exposure to maintenance immunosuppression affects TTV load. We hypothesized that TTV load is associated with the exposure to mycophenolic acid (MPA) and tacrolimus. We performed a prospective study including 54 consecutive KTx. Blood TTV load was measured by an in-house PCR at months 1 and 3. Together with doses and trough blood levels of tacrolimus and MPA, we calculated the coefficient of variability (CV), time in therapeutic range (TTR) and concentration/dose ratio (C/D) of tacrolimus, and the MPA-area under the curve (AUC-MPA) at the third month. TTV load at the first and third month discriminated those patients at risk of developing opportunistic infections between months 1 and 3 (AUC-ROC 0.723, 95%CI 0.559–0.905, p = 0.023) and between months 3 and 6 (AUC-ROC 0.778, 95%CI 0.599–0.957, p = 0.028), respectively, but not those at risk of acute rejection. TTV load did not relate to mean tacrolimus blood level, CV, TTR, C/D and AUC-MPA. To conclude, although TTV is a useful marker of net immunosuppressive status after KTx, it is not related to exposure to maintenance immunosuppression.

8 December 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RNRita Nogueiras-Álvarez
Rita Nogueiras-Álvarez
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
JCJosé Manuel Cifrián-Martínez
José Manuel Cifrián-Martínez
MCMARIA ANGELES DE COS
MARIA ANGELES DE COS
MGMaría del Mar García-Sáiz
María del Mar García-Sáiz
Patients undergoing lung transplantation (LTx) need administration of immunosuppressive therapy following the procedure to prevent graft rejection. However, these drugs are not exempt from potential risks. The development of cardiovascular risk factors and impaired renal function in the post-transplantation period are conditions that may be favoured by the use of calcineurin inhibitor (CNI) drugs which could have repercussions on the quality of life and the post-transplantation evolution. To evaluate the cardiovascular and renal toxicity following the administration of CNI as maintenance immunosuppression in lung transplant recipients (LTRs) we reviewed a total number of 165 patients undergoing LTx between 01/01/2015 and 08/12/2018. They were divided into two groups according to the CNI drug administrated: cyclosporine (CsA-group) with 11 patients or tacrolimus (Tac-group), with 154 patients. We evaluated the de novo occurrence of arterial hypertension (HTN), diabetes mellitus (DM), hyperlipidemia and impaired renal function after initiation of CNI administration. In addition to that, the time until each of these events was assessed. A higher rate for developing HTN (p < 0.001) and impaired renal function (p = 0.047) was observed within the CsA-group. The new onset of hyperlipidemia was similar between both CNI groups and de novo appearance of DM was only documented in those LTRs receiving tacrolimus. In this LTRs retrospective study, it was observed that having ≥ 4 tacrolimus trough levels above the upper limit of the proposed interval for each specific post-LTx period was associated with an increased risk for developing renal impairment. No other statistically significant association was found between supratherapeutic CNIs blood levels and the evaluated toxicities.

23 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
LCLucía Cañamero
Lucía Cañamero
ABAdalberto Benito
Adalberto Benito
EGElena González-López
Elena González-López
CEClara Escagedo
Clara Escagedo
MRMaría Rodríguez-Vidriales
María Rodríguez-Vidriales
EREMILIO RODRIGO
EMILIO RODRIGO
Measuring the non-pathogenic Torque Teno Virus (TTV) load allows assessing the net immunosuppressive state after kidney transplantation (KTx). Currently, it is not known how exposure to maintenance immunosuppression affects TTV load. We hypothesized that TTV load is associated with the exposure to mycophenolic acid (MPA) and tacrolimus. We performed a prospective study including 54 consecutive KTx. Blood TTV load was measured by an in-house PCR at months 1 and 3. Together with doses and trough blood levels of tacrolimus and MPA, we calculate the coefficient of variability (CV), time in therapeutic range (TTR) and concentration/dose ratio (C/D) of tacrolimus, and the MPA-area under the curve (AUC-MPA) at the third month. TTV load at the first and third month discriminated those patients at risk of developing opportunistic infections between months 1 and 3 (AUC-ROC 0.723, 95%CI 0.559-0.905, p = 0.023) and between months 3 to 6 (AUC-ROC 0.778, 95%CI 0.599-0.957, p = 0.028), respectively, but not those at risk of acute rejection. TTV load did not relate to mean tacrolimus blood level, CV, TTR, C/D and AUC-MPA. To conclude, although TTV is a useful marker of net immunosuppressive status after KTx, it is not related to exposure to maintenance immunosuppression.

30 December 2023 in Enfermería Nefrológica
Verified
Journal Article
Open access
PDF file
LALaura Argüeso-Gómez
Laura Argüeso-Gómez
EREMILIO RODRIGO
EMILIO RODRIGO
RPRaquel Pelayo-Alonso
Raquel Pelayo-Alonso
MCMARIA ANGELES DE COS
MARIA ANGELES DE COS
En los pacientes trasplantados renales es un factor clave para la supervivencia del injerto, así como para la calidad de vida de estos pacientes.Objetivo: Analizar la adherencia terapéutica de los pacientes con trasplante renal y su relación con el nivel plasmático de inmunosupresores.Material y Método: Se realizó un estudio observacional, descriptivo, transversal, en una población de trasplantados renales entre diciembre 2021 y enero 2022, del Servicio de Nefrología del Hospital Universitario Marqués de Valdecilla. Para determinar la adherencia al tratamiento inmunosupresor se utilizó el cuestionario simplificado de adherencia a la medicación (SMAQ). Se recogieron otras variables socio-clínicas: edad, sexo, tiempo transcurrido desde el último trasplante, trasplantes renales previos, tipo de trasplante (renal o combinado), nefropatía de base, niveles de inmunosupresores en sangre, inmunosupresor pautado y número total de medicamentos prescritos. En los pacientes con tacrolimus e ImTOR se recogieron niveles de las últimas 5 analíticas, y se calculó la desviación estándar y el coeficiente de variabilidad.Resultados: Se estudiaron 100 pacientes: 7% trasplante combinado riñón-páncreas, 92% tacrolimus como inmunosupresor principal, no adherentes el 29% (sin diferencias por sexo). No se encontraron diferencias estadísticamente significativas entre los niveles de inmunosupresores en sangre y la adherencia al tratamiento inmunosupresor, ni para la totalidad, ni por subgrupos.Conclusiones: La tasa de no adherentes en nuestra muestra es del 29%. No hemos encontrado una asociación estadísticamente significativa entre los niveles de inmunosupresores en sangre y la adherencia al tratamiento.

30 November 2021 in Transplantology
Verified
Journal Article
Open access
PDF file
RNRita Nogueiras-Álvarez
Rita Nogueiras-Álvarez
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
JCJosé Manuel Cifrián
José Manuel Cifrián
MCMARIA ANGELES DE COS
MARIA ANGELES DE COS
MGMaría del Mar García-Saiz
María del Mar García-Saiz
Immunosuppressive therapy reduces the risk for allograft rejection but leaves recipients susceptible to infections. Cytomegalovirus (CMV) is one of the most frequent causes for infection after transplantation and increases the risk for allograft rejection. As lung transplant recipients (LTRs) need to be under immunosuppression for life, they are a vulnerable group. To determine the potential association between the development of CMV infection and the calcineurin inhibitor (CNI) blood levels within previous 90 days, a retrospective review of LTRs was performed. Data from recipients who underwent a lung transplantation (LTx) at our center from January 2011 to December 2018 were collected. The studied recipients, after case/control matching, included 128 CMV-infection cases. The median time from the transplant to the first positive CMV viral load was 291.5 days. In our study, more patients were treated with tacrolimus (91.9%) than with cyclosporine (8.1%). Drug blood levels at selected timepoints showed no statistically significant difference between cases and controls. However, we found that CMV infection was more frequent in the donor-seropositive/recipient-seronegative group, interstitial lung disease (ILD) recipients, LTRs who underwent basiliximab induction, cyclosporine treated recipients, and LTRs with lymphopenia (at the time of CMV infection and 90 days before). In this review of LTRs, no association between the CNI blood level and CMV infection was seen, although other immunity-related factors were found to be influencing, i.e., basiliximab induction, cyclosporine treatment, and lymphopenia.

11 June 2024 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
VDVerónica Aprn Diego-Fernández
Verónica Aprn Diego-Fernández
MGMaría del Mar García-Saiz
María del Mar García-Saiz
ALAna Llorente-Cantalapiedra
Ana Llorente-Cantalapiedra
JAJosé Antonio Aprn Arquero-González
José Antonio Aprn Arquero-González
MBMaría Victoria Aprn Bermúdez-García
María Victoria Aprn Bermúdez-García
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
Background: Following lung transplantation (LT), receiving immunosuppressive therapy is crucial. Tacrolimus is considered a drug with a narrow therapeutic range and its use requires constant monitoring. This study aimed to evaluate the correlation between tacrolimus levels obtained from central venous catheter and direct venipuncture in adult patients undergoing LT. Methods: This prospective study included LT patients hospitalized in conventional ward carrying a central catheter through which no intravenous tacrolimus was administered. Trough samples were obtained through direct puncture and from the central catheter. Pearson correlation coefficient was calculated to quantify the mean difference between the 2 measures. Results: A total of 54 sample pairs from 16 LT patients were obtained, mostly male (81.3%) and bilateral transplant recipients (93.8%); the transplant procedure was the primary reason for admission (81.3%). The difference in tacrolimus levels between both samples was 0.3 (0.1–0.6) mcg/L, with the measurement for the samples obtained through venipuncture being mostly higher than that for those obtained from the catheter. A strong correlation was observed between the tacrolimus levels in the samples obtained from the catheter and through venipuncture (Pearson correlation coefficient, 0.991; P < 0.001; R2 = 0.982). Conclusions: There is an excellent correlation between tacrolimus levels obtained from venipuncture and those obtained from central venous catheter in LT patients undergoing oral tacrolimus therapy.